TOURKANTONIS I[au] - Search Results

Year	Number of Results
2008	4
2009	2
2011	2
2014	2
2015	1
2022	0

1

Tourkantonis IS, Peponi E, Syrigos KN, Saif MW. Tourkantonis IS, et al. JOP. 2014 Jul 28;15(4):335-9. doi: 10.6092/1590-8577/2689. JOP. 2014. PMID: 25076337 Free article.

2

Neuroendocrine cell carcinoma of unknown primary arising in long standing history of multiple sclerosis.

Boussios S, Kostadima V, Batistatou A, Tourkantonis I, Fotopoulos G, Argyropoulou MI, Pavlidis N. Boussios S, et al. Among authors: tourkantonis i. Case Rep Oncol Med. 2015;2015:135976. doi: 10.1155/2015/135976. Epub 2015 Mar 24. Case Rep Oncol Med. 2015. PMID: 25878912 Free PMC article.

3

Renal oncocytoma: a case report and short review of the literature.

Alamara C, Karapanagiotou EM, Tourkantonis I, Xyla V, Maurer CC, Lykourinas M, Pandha H, Syrigos KN. Alamara C, et al. Among authors: tourkantonis i. Eur J Intern Med. 2008 Nov;19(7):e67-9. doi: 10.1016/j.ejim.2008.03.003. Epub 2008 Apr 28. Eur J Intern Med. 2008. PMID: 19013370 Review. No abstract available.

4

Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.

Peponi E, Tourkantonis I, Tasiou I, Pavlidis N, Pentheroudakis G, Tsekeris P. Peponi E, et al. Among authors: tourkantonis i. J BUON. 2014 Jul-Sep;19(3):718-23. J BUON. 2014. PMID: 25261658 Free article.

5

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.

Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN. Syrigou E, et al. Among authors: tourkantonis i. Int Arch Allergy Immunol. 2011;156(3):320-4. doi: 10.1159/000324454. Epub 2011 Jun 29. Int Arch Allergy Immunol. 2011. PMID: 21720178

6

Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.

Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K. Ralli M, et al. Among authors: tourkantonis i. Anticancer Res. 2009 Aug;29(8):3441-4. Anticancer Res. 2009. PMID: 19661370 Free article. Clinical Trial.

7

The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC).

Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I, Syrigos KN. Karapanagiotou EM, et al. Among authors: tourkantonis i. Lung Cancer. 2008 Sep;61(3):391-7. doi: 10.1016/j.lungcan.2008.01.018. Epub 2008 Mar 14. Lung Cancer. 2008. PMID: 18342391

8

Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.

Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Tourkantonis I, et al. Am J Clin Oncol. 2011 Feb;34(1):38-42. doi: 10.1097/COC.0b013e3181cae90e. Am J Clin Oncol. 2011. PMID: 20142722 Clinical Trial.

9

Right sited renal cell carcinoma metastasizing to the contralateral ovary: case report and review of the literature.

Anagnostou VK, Tiniakos DG, Chorti M, Kiagia M, Tourkantonis I, Alamara C, Syrigos KN. Anagnostou VK, et al. Among authors: tourkantonis i. Pathol Oncol Res. 2009 Mar;15(1):123-7. doi: 10.1007/s12253-008-9039-7. Epub 2008 May 21. Pathol Oncol Res. 2009. PMID: 18493874 Free article.

10

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.

Karapanagiotou EM, Charpidou A, Tzannou I, Dilana K, Kotteas E, Tourkantonis I, Kosmas E, Provata A, Syrigos K. Karapanagiotou EM, et al. Among authors: tourkantonis i. Med Oncol. 2008;25(3):303-8. doi: 10.1007/s12032-007-9036-9. Epub 2008 Jan 17. Med Oncol. 2008. PMID: 18204976 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results